Market Overview

Deutsche Bank Downgrades Hologic, Says Core Businesses Face Structural Challenges

Deutsche Bank Downgrades Hologic, Says Core Businesses Face Structural Challenges
Related HOLX
The Daily Biotech Pulse: Nantkwest Reports Positive Cancer Vaccine Trial Results, Sarepta Offering
The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie
Hologic Clears Key Benchmark, Hitting 80-Plus RS Rating (Investor's Business Daily)

Medical diagnostics products maker Hologic, Inc. (NASDAQ: HOLX) is likely to be stifled by secular growth challenges on multiple fronts, Deutsche Bank said in a Thursday note.

The Analyst

Deutsche Bank analyst Dan Leonard downgraded shares of Hologic from Buy to Neutral with a $46 price target. 

The Thesis

Many of Hologic's businesses — breast imaging, U.S. Pap, medical aesthetics — face structural challenges, Leonard said in the note. (See the analyst's track record here.) 

This is despite the management's track record of resolving headwinds and the stock's discounted valuation, the analyst said.

Deutsche Bank is sounding the alarm on a projected deceleration in diagnostic, which accounted for 40 percent of 2017 sales; challenges in GYN Surgical, responsible for 14 percent of 2017 sales; and "the fickle nature and cyclicality" of the medical aesthetics business, which contributed 13 percent of 2017 sales. But the analyst said he is comfortable with the outlook for the breast imaging business, given its strong results over the last six months. 

"Further study of the issues reduces our confidence these challenges will resolve favorably, and thus we see downside to Street organic revenue growth expectations for 2018-2020," Leonard said. 

With upside to numbers unlikely, the analyst said he sees limited opportunity for stock outperformance against the backdrop of an over 20-percent run-up in the stock over the past three months.

Deutsche Bank reduced its 2019-2020 organic revenue forecasts from 4.5 percent to 4 percent, while the Street is estimating 5-percent growth.

The Price Action

Over the past year, Hologic shares are up about 10 percent.

Hologic was down 2.01 percent at $42.97 at the time of publication. 

Related Links:

HTG Molecular's Deal With Merck KGaA 'Provides Further Validation' For EdgeSeq Technology

Piper Jaffray Says Quidel Shares Can Continue To Rise On The Back Of New Deal With Alere

Photo courtesy of Hologic. 

Latest Ratings for HOLX

Oct 2018Morgan StanleyMaintainsEqual-WeightEqual-Weight
Sep 2018Canaccord GenuityMaintainsHoldHold
Sep 2018Canaccord GenuityMaintainsHoldHold

View More Analyst Ratings for HOLX
View the Latest Analyst Ratings

Posted-In: Dan Leonard Deutsche Bank medicalAnalyst Color Downgrades Price Target Analyst Ratings Best of Benzinga


Related Articles (HOLX)

View Comments and Join the Discussion!

Latest Ratings

CPAImperial CapitalDowngrades68.0
PRMWImperial CapitalInitiates Coverage On18.0
TGTKeyBancInitiates Coverage On110.0
QCOMMorgan StanleyUpgrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Gordon Johnson Sees Cleveland-Cliffs Below $4, Initiates With A Sell

Benzinga's Top Upgrades, Downgrades For January 19, 2018